2012;303(7):E899-907
Novo Nordisk submitted an NDA (new drug application) to the FDA on December 18, 2025, which is the formal step companies take when seeking approval for a medication to be marketed for public use
Liraglutide dosage needs continuous monitoring in patients with hepatic or renal impairment, as the medication can cause acute renal failure and exacerbate end-stage renal disease
Sign up for a group that you can realistically attend (faithfully!) and that offers help with areas you have the resources to address, such as dietary changes or weight loss surgery prep
You should work with your counsel when making these decisions, as this is a developing area that can potentially trigger various compliance issues, including issues beyond the scope of these FAQs.
They help with weight loss by reducing ones appetite and increasing the feeling of being full, slowing digestion, and reducing what some refer to as food noise. GLP-1s are a valuable, proven tool when part of a weight-management program that includes lifestyle changes such as healthier eating and increased activity